RU2360922C2 - Агонисты рецептора (vpac2) гипофизарного пептида, активирующего аденилатциклазу (расар), и фармакологические способы их применения - Google Patents

Агонисты рецептора (vpac2) гипофизарного пептида, активирующего аденилатциклазу (расар), и фармакологические способы их применения Download PDF

Info

Publication number
RU2360922C2
RU2360922C2 RU2005103396/13A RU2005103396A RU2360922C2 RU 2360922 C2 RU2360922 C2 RU 2360922C2 RU 2005103396/13 A RU2005103396/13 A RU 2005103396/13A RU 2005103396 A RU2005103396 A RU 2005103396A RU 2360922 C2 RU2360922 C2 RU 2360922C2
Authority
RU
Russia
Prior art keywords
polypeptide
receptor agonist
agonist activity
polypeptide according
vpac2 receptor
Prior art date
Application number
RU2005103396/13A
Other languages
English (en)
Russian (ru)
Other versions
RU2005103396A (ru
Inventor
Уэйн А. ФРОЛАНД (US)
Уэйн А. Фроланд
Дрю Н. КЕЛНЕР (US)
Дрю Н. КЕЛНЕР
Майкл Л. ДЬЮМАС (US)
Майкл Л. ДЬЮМАС
Кларк ПЭН (US)
Кларк ПЭН
Джеймс УИЛЭН (US)
Джеймс УИЛЭН
Ю-чанг Джон ВАНГ (US)
Ю-чанг Джон ВАНГ
Вэй ВАНГ (US)
Вэй ВАНГ
Original Assignee
БАЙЕР ХелсКер ЛЛСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by БАЙЕР ХелсКер ЛЛСи filed Critical БАЙЕР ХелсКер ЛЛСи
Publication of RU2005103396A publication Critical patent/RU2005103396A/ru
Application granted granted Critical
Publication of RU2360922C2 publication Critical patent/RU2360922C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Cell Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
RU2005103396/13A 2002-07-12 2003-07-11 Агонисты рецептора (vpac2) гипофизарного пептида, активирующего аденилатциклазу (расар), и фармакологические способы их применения RU2360922C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39573802P 2002-07-12 2002-07-12
US60/395,738 2002-07-12

Publications (2)

Publication Number Publication Date
RU2005103396A RU2005103396A (ru) 2005-09-20
RU2360922C2 true RU2360922C2 (ru) 2009-07-10

Family

ID=30115918

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005103396/13A RU2360922C2 (ru) 2002-07-12 2003-07-11 Агонисты рецептора (vpac2) гипофизарного пептида, активирующего аденилатциклазу (расар), и фармакологические способы их применения

Country Status (20)

Country Link
US (2) US7378494B2 (enExample)
EP (1) EP1578358A2 (enExample)
JP (1) JP2006506969A (enExample)
CN (1) CN101405298A (enExample)
AR (1) AR040548A1 (enExample)
AU (1) AU2003267990A1 (enExample)
BR (1) BR0312621A (enExample)
CA (1) CA2491279A1 (enExample)
DO (1) DOP2003000669A (enExample)
GT (1) GT200300142A (enExample)
HN (1) HN2003000217A (enExample)
IL (1) IL165499A (enExample)
MX (1) MXPA04012305A (enExample)
PE (1) PE20040677A1 (enExample)
PL (1) PL377025A1 (enExample)
RU (1) RU2360922C2 (enExample)
TW (1) TW200409641A (enExample)
UY (1) UY27893A1 (enExample)
WO (1) WO2004006839A2 (enExample)
ZA (1) ZA200501118B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301431D0 (sv) * 2003-05-19 2003-05-19 Dermagen Novel antimicrobial peptides
US8460243B2 (en) 2003-06-10 2013-06-11 Abbott Diabetes Care Inc. Glucose measuring module and insulin pump combination
US7722536B2 (en) 2003-07-15 2010-05-25 Abbott Diabetes Care Inc. Glucose measuring device integrated into a holster for a personal area network device
EP1713493A4 (en) * 2004-01-27 2009-06-24 Bayer Pharmaceuticals Corp PEPTIDE-RECEPTOR (VPAC2) AGONISTS THAT ACTIVATE HYPOPHYSIC ADENYLATE CYCLASE (PACAP) AND PHARMACOLOGICAL METHODS OF USING THESE AGONISTS
US20080096811A1 (en) * 2004-05-21 2008-04-24 Eli Lilly And Company Selective vpac2 receptor peptide agonists
CA2564740A1 (en) * 2004-05-21 2005-12-01 Eli Lilly And Company Selective vpac2 receptor peptide agonists
WO2005119524A2 (en) 2004-06-04 2005-12-15 Therasense, Inc. Diabetes care host-client architecture and data management system
EP1768686A4 (en) * 2004-06-12 2007-11-14 Bayer Pharmaceuticals Corp PEGYLATION OF VASOACTIVE INTESTINAL PEPTIDE (VIP) / HYPOPHYDE-ADENYLATE CYCLASE-ACTIVATING PEPTIDE (PACAP) RECEPTOR 2 (VPAC2) AGONISTS AND METHOD OF USE
CA2577010A1 (en) * 2004-08-18 2006-03-02 Eli Lilly And Company Selective vpac2 receptor peptide agonists
US20080085860A1 (en) * 2004-08-18 2008-04-10 Eli Lilly And Company Selective Vpac2 Receptor Peptide Agonists
US20090170775A1 (en) * 2004-10-08 2009-07-02 Transition Therapeutics, Inc. Vasoactive intestinal polypeptide compositions
US7595294B2 (en) 2004-10-08 2009-09-29 Transition Therapeutics, Inc. Vasoactive intestinal polypeptide pharmaceuticals
US20070293429A1 (en) * 2004-10-08 2007-12-20 Therapei Pharmaceuticals, Inc. Vasoactive Intestinal Polypeptide Compositions
WO2006042152A2 (en) 2004-10-08 2006-04-20 Forbes Medi-Tech (Research) Inc. Vasoactive intestinal polypeptide pharmaceuticals
US20080214440A1 (en) * 2004-10-08 2008-09-04 Forbes Medi-Tech (Research), Inc. Vasoactive intestinal polypeptide compositions
US20060159737A1 (en) * 2004-11-19 2006-07-20 Steffen Panzner Pharmaceutical compositions for local administration
ATE432322T1 (de) * 2004-12-21 2009-06-15 Lubrizol Ltd Zusammensetzungen
WO2006110551A2 (en) * 2005-04-08 2006-10-19 Amylin Pharmaceuticals, Inc. Pharmaceutical formulations comprising incretin peptide and aprotic polar solvent
EP1896048A4 (en) * 2005-05-06 2010-11-03 Bayer Pharmaceuticals Corp PEPTIDE RECEPTOR (VPAC2) AGONISTS THAT ACTIVATE HYPOPHYSIC ADENYLATE CYCLASE (PACAP) AND THEIR PHARMACOLOGICAL METHODS OF USE
EP1915393A1 (en) * 2005-08-11 2008-04-30 Eli Lilly And Company Selective vpac2 receptor peptide agonists
US7582608B2 (en) * 2005-10-26 2009-09-01 Eli Lilly And Company Selective VPAC2 receptor peptide agonists
BRPI0708341A2 (pt) * 2006-02-28 2011-05-24 Lilly Co Eli agonistas peptìdicos seletivos do receptor vpac2
EP2011506A1 (en) * 2007-07-05 2009-01-07 Nestec S.A. Supplementation of maternal diet
DK2321640T3 (en) * 2008-08-21 2017-02-27 Immunogenics Llc FORMULATION FOR ORAL ADMINISTRATION OF PROTEINS
US10136845B2 (en) 2011-02-28 2018-11-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
CN106794217A (zh) * 2014-08-06 2017-05-31 血管生物科学 包含对患病组织具有选择性的药效团的组合物及其制备方法
TWI721976B (zh) 2015-04-16 2021-03-21 美商艾爾德生物製藥股份有限公司 抗ｐａｃａｐ抗體及其用途
EP3426288A4 (en) 2016-04-15 2019-10-30 Alder Biopharmaceuticals, Inc. ANTI-PACAP ANTIBODIES AND USES THEREOF

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972319B1 (en) * 1999-09-28 2005-12-06 Bayer Pharmaceuticals Corporation Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GOURLET P. et al. Biochem. Pharmacol. 1997, 54 (4), 509-515. GOURLET P. et al. Eur. J. Pharmacol. 1998, 348 (1), 95-99. NICOLE P. et al. J. Biol. Chem. 2000, 275 (31), 24003-24012. *

Also Published As

Publication number Publication date
GT200300142A (es) 2004-03-17
HN2003000217A (es) 2004-07-26
MXPA04012305A (es) 2005-02-25
RU2005103396A (ru) 2005-09-20
US20090258826A1 (en) 2009-10-15
IL165499A (en) 2010-12-30
UY27893A1 (es) 2003-12-31
DOP2003000669A (es) 2004-01-31
CN101405298A (zh) 2009-04-08
EP1578358A2 (en) 2005-09-28
US20040058870A1 (en) 2004-03-25
ZA200501118B (en) 2006-08-30
IL165499A0 (en) 2006-01-15
PE20040677A1 (es) 2004-10-29
TW200409641A (en) 2004-06-16
AR040548A1 (es) 2005-04-13
CA2491279A1 (en) 2004-01-22
US7378494B2 (en) 2008-05-27
JP2006506969A (ja) 2006-03-02
WO2004006839A2 (en) 2004-01-22
AU2003267990A1 (en) 2004-02-02
PL377025A1 (pl) 2006-01-23
BR0312621A (pt) 2005-12-06

Similar Documents

Publication Publication Date Title
RU2360922C2 (ru) Агонисты рецептора (vpac2) гипофизарного пептида, активирующего аденилатциклазу (расар), и фармакологические способы их применения
US7524813B2 (en) Selectively conjugated peptides and methods of making the same
CN108026153B (zh) 作为选择性肽双重glp-1/胰高血糖素受体激动剂的新毒蜥外泌肽-4衍生物
EP3321279B1 (en) Exenatide modifier and use thereof
UA62967C2 (en) Peptide analogs of parathyroid hormons
US11612640B2 (en) Acylated GLP-1 derivative
WO2005035553A2 (en) Conjugation of peptides
CA2094512A1 (en) Fusion polypeptides
JP2010523477A (ja) 線維芽細胞活性化タンパク質の阻害剤、およびそれを使用する方法
Gajewiak et al. Selective penicillamine substitution enables development of a potent analgesic peptide that acts through a non-opioid-based mechanism
JP2018531217A6 (ja) エキセナチド修飾物及びその用途
EP3604538A1 (en) Long-acting adrenomedullin derivative
CN109248323B (zh) 酰化的glp-1衍生物
AU2020234373B9 (en) Novel peptide and use thereof
JP2016504379A (ja) Ｎ−末端の電荷が改変されたインスリン分泌ペプチド誘導体
JP2022519389A (ja) グルカゴン様ペプチド－１（ｇｌｐ－１）アゴニストのアナログ、その調製プロセスおよび使用
WO2020228610A1 (zh) 多肽衍生物及其制备方法
JPH08269091A (ja) 新規ペプチド及びそれを有効成分とする骨疾患治療薬
RU2792236C9 (ru) Производное полипептида и способ его получения
RU2792236C1 (ru) Производное полипептида и способ его получения
RU2783776C1 (ru) Новый пептид и его применение
Merlino et al. Expanding Structure–Activity Relationships of Human Urotensin II Peptide Analogues: A Proposed Key Role of the N-Terminal Region for Novel Urotensin II Receptor Modulators
MPharm Peptide-mimetic hydrogels as a long-acting drug delivery platform for HIV/AIDS
WO1999051627A1 (fr) Methode de recherche de substances physiologiquement actives, procede de production de ces substances et medicaments decouverts par la methode de recherche
JP2003221400A (ja) 新規ペプチド及びそれを有効成分とする骨疾患治療薬

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20100712